Clinical Trial Update: Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) [Phase 2]

View source ↗

Summary

Phase 2 trial KEYNOTE-654-05/ECHO-305-05 comparing pembrolizumab plus epacadostat versus pembrolizumab plus placebo in metastatic non-small cell lung cancer has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Epacadostat (epacadostat)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Incyte Corporation | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-02-05